Driving disruption in the solid tumor space: is it time to shift paradigms and develop novel immuno-oncology strategies?

Roisin McGuigan, Editor, Cell & Gene Therapy Insights, speaks to Edward Patz, Chief Executive Officer, Grid Therapeutics, LLC; James and Alice Chen Distinguished Professor of Radiology, Professor in Pharmacology and Cancer Biology, Duke University School of Medicine

Edward Patz, Jr is a founder and the CEO of Grid Therapeutics. He is also the James and Alice Chen Distinguished Professor of Radiology and a Professor in Pharmacology and Cancer Biology at Duke University School of Medicine. He began his training in High Energy Physics at Harvard University, received his MD from the University of Maryland, completed his residency and thoracic imaging fellowship at the Brigham and Women’s Hospital and Harvard Medical School, and then was appointed to the faculty in the Department of Radiology at the Brigham, Harvard Medical School, and the Dana Farber Cancer Institute. In 1991, he was recruited to the Thoracic Imaging section in the Department of Radiology at Duke. Dr Patz is a clinician–scientist, with over 200 publications, and has participated in numerous clinical trials including the National Lung Cancer Screening Trial (NLST). For over 25 years, he has been the principal investigator of a basic science laboratory that explores clonal evolution of tumors, biomarkers for early detection, and the role of inflammation in cancer.